US4021492A
(en)
*
|
1975-03-24 |
1977-05-03 |
Sandoz, Inc. |
Dibromination process
|
SE414305B
(sv)
*
|
1976-08-25 |
1980-07-21 |
Astra Laekemedel Ab |
Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
|
US4318791A
(en)
*
|
1977-12-22 |
1982-03-09 |
Ciba-Geigy Corporation |
Use of aromatic-aliphatic ketones as photo sensitizers
|
FR2430933A1
(fr)
*
|
1978-07-13 |
1980-02-08 |
Synthelabo |
Derives de propiophenone et leur application en therapeutique
|
US4347257A
(en)
*
|
1979-10-09 |
1982-08-31 |
Burroughs Wellcome Co. |
Prolactin suppression in mammals
|
FR2486074A1
(fr)
*
|
1979-12-14 |
1982-01-08 |
Lafon Labor |
Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
|
EP0038071B1
(de)
*
|
1980-04-14 |
1984-11-14 |
The Wellcome Foundation Limited |
Radioaktiv markierte und unmarkierte Butylaminopropiophenon-Derivate, ihre Herstellung, aus den unmarkierten Derivaten erzeugte Immunogene und ein Verfahren zur Herstellung der Antisera, durch Immunogen hergestellte Antisera und Verfahren zur Herstellung der Antisera, ein Radioimmunoassayverfahren und eine Reagentiengarnitur zum Gebrauch bei dieser Methode
|
ATE8987T1
(de)
*
|
1981-03-23 |
1984-09-15 |
Laboratoire L. Lafon Societe Anonyme Dite: |
Fluorphenacyl-amin-derivate und ihre therapeutische verwendung.
|
JPS57169450A
(en)
*
|
1981-04-13 |
1982-10-19 |
Lafon Labor |
Fluorophenacyl-amine derivative and application to remedy
|
US4393078A
(en)
*
|
1982-03-15 |
1983-07-12 |
Burroughs Wellcome Co. |
Bupropion and ethanol
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
US4507323A
(en)
*
|
1984-07-25 |
1985-03-26 |
Burroughs Wellcome Co. |
Treatment of psychosexual dysfunctions
|
FR2569184A1
(fr)
*
|
1984-08-20 |
1986-02-21 |
Lafon Labor |
Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
|
US5236922A
(en)
*
|
1984-08-20 |
1993-08-17 |
Laboratoire L. Lafon |
Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives
|
FR2569185B1
(fr)
*
|
1984-08-20 |
1986-09-05 |
Lafon Labor |
Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
|
GB9217295D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5358970A
(en)
*
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5753712A
(en)
*
|
1994-02-18 |
1998-05-19 |
Pinsker; Walter |
Treatment of migraine headaches and formulations
|
WO1995022324A1
(en)
*
|
1994-02-18 |
1995-08-24 |
Walter Pinsker |
Treatment of migraine headaches and formulations
|
US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6458374B1
(en)
|
1998-01-29 |
2002-10-01 |
Sepracor, Inc. |
Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
|
JP2002501892A
(ja)
*
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(−)−ビュープロピオンの薬学的使用
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
EP2301537A1
(de)
*
|
2002-05-17 |
2011-03-30 |
Duke University |
Zonisamid zur Behandlung von Fettleibigkeit
|
JP5084103B2
(ja)
*
|
2002-07-18 |
2012-11-28 |
サイトス バイオテクノロジー アーゲー |
ハプテン担体抱合体およびその用法
|
WO2004024674A1
(en)
*
|
2002-09-10 |
2004-03-25 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Process for the preparation of bupropion hydrochloride
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
ITMI20030762A1
(it)
*
|
2003-04-11 |
2004-10-12 |
Erregierre Spa |
Processo di cristallizzazione del bupropione cloridrato.
|
SI2316456T1
(sl)
*
|
2003-04-29 |
2017-10-30 |
Orexigen Therapeutics, Inc. |
Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
|
US8802139B2
(en)
*
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
KR100828218B1
(ko)
|
2003-09-12 |
2008-05-07 |
화이자 인코포레이티드 |
알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
WO2005070461A2
(en)
|
2004-01-13 |
2005-08-04 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
WO2007002597A2
(en)
*
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
EP2317316A3
(de)
|
2005-07-08 |
2011-06-15 |
Braincells, Inc. |
Verfahren zur Identifizierung von neurogenesemodulierenden Wirkstoffen und Bedingungen
|
EP2258359A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP1945198A4
(de)
*
|
2005-10-14 |
2009-08-26 |
Lundbeck & Co As H |
Stabile pharmazeutische formulierungen mit escitalopram und bupropion
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
EP2135603B1
(de)
|
2005-11-22 |
2013-01-02 |
Orexigen Therapeutics, Inc. |
Zusammensetzungen und Verfahren zur Erhöhung der Insulinsensitivität
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
MX2008008694A
(es)
*
|
2006-01-03 |
2009-01-07 |
Algebra Inc |
Compuestos conjugados de amina terapeutica-arilsulfonamida.
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2648280C
(en)
*
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
WO2007117581A2
(en)
*
|
2006-04-06 |
2007-10-18 |
Collegium Pharmaceutical, Inc. |
Stabilized transdermal bupropion preparations
|
EP2377531A2
(de)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenese mittels Angiotensin-Modulation
|
EP2026813A2
(de)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5-ht-rezeptor-vermittelte neurogenese
|
US10960077B2
(en)
*
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
KR101735466B1
(ko)
|
2006-11-09 |
2017-05-15 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
KR20150082689A
(ko)
|
2006-11-09 |
2015-07-15 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
MX2009013989A
(es)
*
|
2007-06-18 |
2010-03-09 |
Gen Hospital Corp |
Terapia en combinacion para depresion.
|
CN100560563C
(zh)
*
|
2007-07-06 |
2009-11-18 |
浙江普洛医药科技有限公司 |
盐酸安非他酮的合成方法
|
US20090076161A1
(en)
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bupropion
|
US20090148541A1
(en)
*
|
2007-10-16 |
2009-06-11 |
Duke University |
Compositions and methods for the treatment of seborrhea
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
CA2725930A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
US8450376B2
(en)
*
|
2008-06-16 |
2013-05-28 |
Glenmark Generics Ltd. |
Amorphous bupropion hydrobromide and preparation thereof
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2010121022A1
(en)
|
2009-04-15 |
2010-10-21 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
CN102724878A
(zh)
|
2010-01-11 |
2012-10-10 |
奥雷西根治疗公司 |
在重度抑郁症患者中提供体重减轻疗法的方法
|
DK3730132T3
(da)
|
2012-06-06 |
2022-08-08 |
Nalpropion Pharmaceuticals Llc |
Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko
|
US11433067B2
(en)
|
2013-11-05 |
2022-09-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10512643B2
(en)
|
2013-11-05 |
2019-12-24 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10874664B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11229640B2
(en)
|
2013-11-05 |
2022-01-25 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US10864209B2
(en)
|
2013-11-05 |
2020-12-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11478468B2
(en)
|
2013-11-05 |
2022-10-25 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11571399B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11141416B2
(en)
|
2013-11-05 |
2021-10-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11344544B2
(en)
|
2013-11-05 |
2022-05-31 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11419867B2
(en)
|
2013-11-05 |
2022-08-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426370B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123344B2
(en)
|
2013-11-05 |
2021-09-21 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US10780064B2
(en)
|
2019-01-07 |
2020-09-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576877B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as modulator of drug activity
|
US20220233470A1
(en)
|
2013-11-05 |
2022-07-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617747B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11439636B1
(en)
|
2013-11-05 |
2022-09-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11590124B2
(en)
|
2013-11-05 |
2023-02-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11007189B2
(en)
|
2013-11-05 |
2021-05-18 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10933034B2
(en)
|
2013-11-05 |
2021-03-02 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11510918B2
(en)
|
2013-11-05 |
2022-11-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9474731B1
(en)
|
2013-11-05 |
2016-10-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US9457023B1
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11197839B2
(en)
|
2013-11-05 |
2021-12-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9408815B2
(en)
|
2013-11-05 |
2016-08-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11234946B2
(en)
|
2013-11-05 |
2022-02-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576909B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894046B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10945973B2
(en)
|
2013-11-05 |
2021-03-16 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9198905B2
(en)
|
2013-11-05 |
2015-12-01 |
Antecip Bioventures Ii Llc |
Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
|
US11273133B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9402843B2
(en)
|
2013-11-05 |
2016-08-02 |
Antecip Bioventures Ii Llc |
Compositions and methods of using threohydroxybupropion for therapeutic purposes
|
US11065248B2
(en)
|
2013-11-05 |
2021-07-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9968568B2
(en)
|
2013-11-05 |
2018-05-15 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10874663B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11311534B2
(en)
|
2013-11-05 |
2022-04-26 |
Antecip Bio Ventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11058648B2
(en)
|
2013-11-05 |
2021-07-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20160324807A1
(en)
|
2013-11-05 |
2016-11-10 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11596627B2
(en)
|
2013-11-05 |
2023-03-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11207281B2
(en)
|
2013-11-05 |
2021-12-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9700528B2
(en)
|
2013-11-05 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11291665B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11096937B2
(en)
|
2013-11-05 |
2021-08-24 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11291638B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10940124B2
(en)
|
2019-01-07 |
2021-03-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10105327B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
|
US11129826B2
(en)
|
2013-11-05 |
2021-09-28 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US11357744B2
(en)
|
2013-11-05 |
2022-06-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11534414B2
(en)
|
2013-11-05 |
2022-12-27 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253492B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9707191B2
(en)
|
2013-11-05 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11617728B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11090300B2
(en)
|
2013-11-05 |
2021-08-17 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426401B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123343B2
(en)
|
2013-11-05 |
2021-09-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10105361B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10874665B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11191739B2
(en)
|
2013-11-05 |
2021-12-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273134B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10786469B2
(en)
|
2013-11-05 |
2020-09-29 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10980800B2
(en)
|
2013-11-05 |
2021-04-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11298352B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285118B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10080727B2
(en)
|
2013-11-05 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US20160361305A1
(en)
|
2013-11-05 |
2016-12-15 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US11541021B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10688066B2
(en)
|
2018-03-20 |
2020-06-23 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11382874B2
(en)
|
2013-11-05 |
2022-07-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11524007B2
(en)
|
2013-11-05 |
2022-12-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10813924B2
(en)
|
2018-03-20 |
2020-10-27 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11147808B2
(en)
|
2013-11-05 |
2021-10-19 |
Antecip Bioventures Ii Llc |
Method of decreasing the fluctuation index of dextromethorphan
|
US9457025B2
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US10898453B2
(en)
|
2013-11-05 |
2021-01-26 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11571417B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253491B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11298351B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11185515B2
(en)
|
2013-11-05 |
2021-11-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11020389B2
(en)
|
2013-11-05 |
2021-06-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11364233B2
(en)
|
2013-11-05 |
2022-06-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10799497B2
(en)
|
2013-11-05 |
2020-10-13 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US9861595B2
(en)
|
2013-11-05 |
2018-01-09 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10966974B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20200338022A1
(en)
|
2019-01-07 |
2020-10-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11541048B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10772850B2
(en)
|
2013-11-05 |
2020-09-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11517543B2
(en)
|
2013-11-05 |
2022-12-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894047B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966941B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llp |
Bupropion as a modulator of drug activity
|
US11213521B2
(en)
|
2013-11-05 |
2022-01-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9867819B2
(en)
|
2013-11-05 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US9763932B2
(en)
|
2013-11-05 |
2017-09-19 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10966942B2
(en)
|
2019-01-07 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11497721B2
(en)
|
2013-11-05 |
2022-11-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285146B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10881657B2
(en)
|
2013-11-05 |
2021-01-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9732031B2
(en)
|
2013-12-20 |
2017-08-15 |
Deuterx, Llc |
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
|
CN106699527A
(zh)
*
|
2016-12-07 |
2017-05-24 |
三峡大学 |
一种间氯苯丙酮的合成方法
|
US10925842B2
(en)
|
2019-01-07 |
2021-02-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|